• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » RenovaCare touts data from 44-patient SkinGun burn treatment retrospective analysis

RenovaCare touts data from 44-patient SkinGun burn treatment retrospective analysis

January 30, 2018 By Fink Densford

RenovaCare's SkinGun

RenovaCare today released results from a retrospective analysis of 44 patients with severe second-degree wide-area burn injuries who were treated with the technology underlying the company’s SkinGun and CellMist system.

Results from the analysis were published in the peer-reviewed journal Burns, the company said.

“Treated patients presented with a variety of burn wound etiologies and a wide range of TBSA (Total Burn Surface Area). Overall clinical results were very satisfying,” study authors wrote in a press release.

The 44 patients in the analysis were treated through a method which involved isolating and spraying the patients’ skin stem cells onto burn wounds, which RenovaCare said uses technology its SkinGun and CellMist system are based off of.

Patients in the analysis were treated for deep partial-thickness burns, including gas and chemical explosions and electrical, gasoline, hot water and tar scalding burns, RenovaCare said.

According to data from the published analysis, use of the technology on such burn wounds “can achieve rapid wound re-epithelialization, particularly in large wounds.” Average days to healing and discharge in the analysis were low, regardless of the severity or size of the wound, the company said.

“This data is especially compelling because patients were successfully treated for a broad spectrum of burn injuries and vast burn surface areas. Importantly, patients had very short hospital stays, which, we believe could deliver a better healing experience for patients and lower costs for hospitals and insurance providers. The clinical outcomes and minimal hospital stays for severe burn patients published in this article supports our conviction to bring our SkinGun technology to market as quickly as possible. Presently, we’re finalizing the requisite documentation for filing with the FDA to demonstrate the safety of our approach for treating wounds using a patient’s own skin cells,” RenovaCare prez & CEO Thomas Bold said in a prepared statement.

Last October, RenovaCare said it raised $2.3 million in a new direct offering to support its SkinGun technology.

Filed Under: Clinical Trials, Wound Care Tagged With: RenovaCare

More recent news

  • Medtronic earns CE mark for redo TAVI procedure
  • Natus Neuro launches BrainWatch AI-driven, point-of-care EEG
  • Boston Scientific has positive real-world Acurate Prime TAVI data
  • Johnson & Johnson MedTech launches ultrasound catheter for imaging in cardiac ablation procedures
  • Onward reports more successful BCI implants

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy